CA2233558A1 - Method and pharmaceutical composition for regulating lipid concentration - Google Patents

Method and pharmaceutical composition for regulating lipid concentration

Info

Publication number
CA2233558A1
CA2233558A1 CA002233558A CA2233558A CA2233558A1 CA 2233558 A1 CA2233558 A1 CA 2233558A1 CA 002233558 A CA002233558 A CA 002233558A CA 2233558 A CA2233558 A CA 2233558A CA 2233558 A1 CA2233558 A1 CA 2233558A1
Authority
CA
Canada
Prior art keywords
combination
methylethyl
pharmaceutical composition
lipid concentration
regulating lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002233558A
Other languages
French (fr)
Other versions
CA2233558C (en
Inventor
Thomas Michael Andrew Bocan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner-Lambert Company
Thomas Michael Andrew Bocan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company, Thomas Michael Andrew Bocan filed Critical Warner-Lambert Company
Priority claimed from PCT/US1996/015854 external-priority patent/WO1997016184A1/en
Publication of CA2233558A1 publication Critical patent/CA2233558A1/en
Application granted granted Critical
Publication of CA2233558C publication Critical patent/CA2233558C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is a combination of an ACAT inhibitor for example, sulfamic acid, [[2,4,6; tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester, and an HMG-CoA-reductase inhibitor, for example, atorvastatin, effective for lipid regulation. The combination of agents results in a greater reduction in plasma VLDL and LDL
cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoprotein profile. The combination is useful in the treatment of patients with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.
CA002233558A 1995-11-02 1996-10-02 Method and pharmaceutical composition for regulating lipid concentration Expired - Fee Related CA2233558C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US615595P 1995-11-02 1995-11-02
US60/006,155 1995-11-02
PCT/US1996/015854 WO1997016184A1 (en) 1995-11-02 1996-10-02 Method and pharmaceutical composition for regulating lipid concentration

Publications (2)

Publication Number Publication Date
CA2233558A1 true CA2233558A1 (en) 1997-05-09
CA2233558C CA2233558C (en) 2005-12-06

Family

ID=35519705

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002233558A Expired - Fee Related CA2233558C (en) 1995-11-02 1996-10-02 Method and pharmaceutical composition for regulating lipid concentration

Country Status (1)

Country Link
CA (1) CA2233558C (en)

Also Published As

Publication number Publication date
CA2233558C (en) 2005-12-06

Similar Documents

Publication Publication Date Title
NZ512484A (en) Regulating lipid concentration in mammals by administering an acyl-CoA cholesterol O-acyltransferase (ACAT) inhibitor and an HMG-CoA reductase inhibitor
AU3720295A (en) Ribozyme treatment of diseases or conditions related to levels of plasma lipoprotein (a) {lp(a)} by inhibiting apolipoprotein (a) {apo(a)}
BG101993A (en) Dialkylethers containing end carboxylic or tetrazole groups
BR9307035A (en) Process for reducing blood levels of total cholesterol and low density lipoprotein cholesterol
CA2210996A1 (en) Liquid formulations for proteinic pharmaceuticals
AU5074196A (en) Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
MX9308053A (en) COMBINATION OF A CHOLESTEROL BIOSYNTHESIS INHIBITOR AND A ß-LACTAM CHOLESTEROL ABSORPTION INHIBITOR.
AU6029096A (en) Compositions and methods for topical administration of pharm aceutically active agents
CA2045885A1 (en) Inhibition of mammalian muscle wasting and protein degradation by tetracyclines
AU6311694A (en) Device for the direct measurement of low density lipoprotein cholesterol
NO984524L (en) Amphipathic molecules such as cholesterol and other lipid uptake inhibitors
DE69115909T2 (en) Use of phospholipids for the manufacture of a topical medication for influencing serum cholesterol levels
NO862750D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE OXINDOL DERIVATIVES.
AU702443C (en) Method for determinaton of cholesterol in low-density lipoprotein
NO995928L (en) Alpha-1-antitrypsin preparations and their method of preparation
CA2233558A1 (en) Method and pharmaceutical composition for regulating lipid concentration
AU5544994A (en) Use of 17alpha-dihydroequilenin for lowering cholesterol
CA2049119A1 (en) Lipoprotein removal by soluble enzymes
Luoma et al. Lipid peroxides, glutathione peroxidase, high density lipoprotein subfractions and apolipoproteins in young adults
NO934832L (en) Pharmaceutical composition for the prevention or treatment of arterioscherosis
AU4525796A (en) Methods and materials for the immunoassay of apolipoprotein(a) and lipoprotein(a)
AU7533194A (en) Use of centrally effective alpha-2 agonists for inhibiting postaggression metabolism
Galle et al. Oxidized lipoprotein (a) inhibits endothelium-dependent dilation: prevention by high density lipoprotein
Tateossian et al. Variations in HDL and VLDL levels chronic alcoholics. Influence of the degree of liver damage and of withdrawal of alcohol
WO2001041706A3 (en) Lipid nanotubules for topical delivery

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed